Vaxart to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Sep 16, 2021 12:40 PM ET
Legal Newswire POWERED BY LAW.COM
Vaxart, Inc. announced that Andrei Floroiu, President and CEO, and Dr. Sean Tucker, SVP and Chief Scientific Officer, will present at the H.C. Wainwright 23rd Annual Global Investor Conference taking place Sept. 13-15, 2021.
The presentation will be available on demand through the H.C. Wainwright conference portal beginning at 7:00 a.m. ET on Monday, Sept. 13, 2021, and on Vaxart's The Company will also participate in one-on-one meetings during the conference.
Vaxart's oral tablet COVID-19 vaccine is "The Pill that Moves the Needle" and the only oral COVID-19 vaccine whose potential is backed by clinical data. The Company's oral tablet COVID-19 vaccine candidate has completed phase I trials and will enter phase II clinical trials this year.
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart's development programs currently include tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza, and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immuno-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
Vaxart Media Relations:
Tags: Wire, Legal Newswire, United States, English